Y-mAbs Therapeutics, Inc. (YMAB)

Market Cap	182.68M
Revenue (ttm)	87.69M
Net Income (ttm)	-29.67M
Shares Out	45.22M
EPS (ttm)	-0.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	109,422
Open	3.870
Previous Close	3.880
Day's Range	3.760 - 4.070
52-Week Range	3.840 - 17.470
Beta	0.52
Analysts	Buy
Price Target	18.73 (+363.61%)
Earnings Date	May 13, 2025

About YMAB

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma an...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 21, 2018
• Employees: 104
• Stock Exchange: NASDAQ
• Ticker Symbol: YMAB
• Website: https://www.ymabs.com

Financial Performance

In 2024, Y-mAbs Therapeutics's revenue was $87.69 million, an increase of 3.38% compared to the previous year's $84.82 million. Losses were -$29.67 million, 38.5% more than in 2023.

Analyst Forecast

According to 11 analysts, the average rating for YMAB stock is "Buy." The 12-month stock price forecast is $18.73, which is an increase of 363.61% from the latest price.

Price Target

$18.73

(363.61% upside)

Analyst Consensus: Buy